Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: Multi-Omics Analysis of End-Stage Renal Disease

PROVIDER: PRJNA832919 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR18960830_1.fastq.gz	Fastqsanger.gz
	SRR18960830_2.fastq.gz	Fastqsanger.gz
	SRR18960831_1.fastq.gz	Fastqsanger.gz
	SRR18960831_2.fastq.gz	Fastqsanger.gz
	SRR18960832_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 87

Similar Datasets

Understanding the biological processes of clear cell renal carcinoma carcinogenesis: an integrative multi-omics approach.

Project description:Multi-Omics analysis to gain novel insights into clear cell renal carcinoma aetiology and progression. The DNA methylation data of 121 clear clear renal carcinoma (ccRCC) were integrated with WGS and transcriptomic data using Multi-Omics Factor Analysis (MOFA) to detect the inter-patient variations related to aetiological and disease progression related factors.

2024-06-07 | GSE269180 | GEO

Homo sapiens

Project description:Genomic profiling of renal cell carcinoma in patients with end-stage renal disease

| PRJNA139103 | ENA

Genomic profiling of 19 renal cell carcinoma samples from patients with end-stage renal disease

Project description:In this study, 19 tumor samples from patients with renal cell carcinoma (RCC)-end-stage renal disease (ESRD) were analyzed by array comparative genomic hybridization (array CGH) using the Agilent Whole Human Genome 4× Array.

2012-04-02 | GSE33117 | GEO

Quantitative proteomic analysis of hypoxia induced primary kidney cells

Project description:Chronic kidney disease (CKD) is characterized by a slow and gradual loss of kidney function, with glomerular filtration loss over months or years, inevitably leading to end-stage renal disease. The renal failure resulting from this irreversible process derives from fibrotic lesions of each compartment of the kidney; glomerulosclerosis, vascular sclerosis, and tubulointerstitial fibrosis. Nevertheless, despite numerous research efforts, both the definitive mechanism underlying the progression from CKD to end stage renal disease and an effective treatment have remained elusive. In this study, We utilized TMT-multiplexed quantitative proteomics approaches to identify protein expression changes associated with chronic injury in primary cultured renal cells.

2021-01-19 | PXD019678 | Pride

Genomic profiling of renal cell carcinoma in patients with end-stage renal disease

Project description:In this study, eighty tumor samples from 63 patients with renal cell carcinoma (RCC)-end-stage renal disease (ESRD) were analyzed by array comparative genomic hybridization (array CGH) using the Agilent Whole Human Genome 4×44K Oligo Micro Array.

2012-03-24 | GSE28601 | GEO

Homo sapiens

Project description:Plasma transcriptome profiling in patients with chronic kidney disease and end-stage renal disease

| PRJNA382706 | ENA

Homo sapiens

Project description:Genomic profiling of 19 renal cell carcinoma samples from patients with end-stage renal disease

| PRJNA149363 | ENA

In-depth proteome profiling of kidney in 5/6 Nephrectomy rat model

2021-01-19 | PXD016447 | Pride

Multi-omic analysis of homologous recombination deficient, end-stage ovarian cancer [Methylation]

Project description:High grade serous ovarian cancer (HGSC) is frequently characterized by homologous recombination (HR) DNA repair deficiency, and while most such tumors are sensitive to initial treatment, acquired resistance is common. We undertook a multi-omics approach to interrogate the molecular diversity in end-stage disease, using multiple autopsy samples collected from 15 women with HR-deficient HGSC. Patients had polyclonal disease, and several resistance mechanisms were identified within most patients, including reversion mutations and HR restoration by other means. We also observed frequent whole genome duplication, and global changes in immune composition with evidence of immune escape. This analysis highlights diverse evolutionary changes within HGSC that conspire to evade therapy and ultimately overwhelm individual patients. Methylation profiling was done on 29 end stage high grade serous ovarian cancer samples. 38 primary tumours, 6 autopsy tumours and 7 fallopian tube normals from GSE65820 were also used as part of the cohort.

2022-11-12 | GSE217673 | GEO